<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982436</url>
  </required_header>
  <id_info>
    <org_study_id>VCC 0905</org_study_id>
    <nct_id>NCT00982436</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer</brief_title>
  <official_title>A Pilot Study to Evaluate Response to Neoadjuvant Chemotherapy With Cisplatin and Docetaxel Followed by Chemoradiation Therapy With Carboplatin in Stage IV Non-metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of neoadjuvant
      chemotherapy (chemotherapy given before radiotherapy) using cisplatin and docetaxel, followed
      by carboplatin given at the same time as radiotherapy in the treatment of locally advanced
      head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemoradiotherapy has become the standard of care for patients with unresectable head and
      neck cancer, but there can be substantial added toxicity with chemoradiotherapy compared to
      radiation therapy alone. Neoadjuvant therapy with cisplatin / 5-fluorouracil has demonstrated
      activity in this disease, and taxanes appear to improve response further. Docetaxel /
      cisplatin / 5-fluorouracil has been shown to be a highly active regimen. However, with the
      potential added toxicities of neoadjuvant chemotherapy, it is important to minimize toxicity
      while maintaining efficacy. Chemotherapeutic agents that are DNA cycle-specific like
      5-fluorouracil are more stomatotoxic than those that are cell phase non-specific. Of note,
      several studies have suggested that docetaxel and cisplatin is a highly active combination
      when used for advanced disease or as neoadjuvant therapy .

      This study will therefore test the efficacy of neoadjuvant chemotherapy with cisplatin and
      docetaxel without 5-fluorouracil followed by chemoradiotherapy with carboplatin to determine
      whether promising response rates with modest toxicity can be achieved. Carboplatin will be
      used as the radiosensitizing agent during chemoradiotherapy to reduce nephrotoxicity and
      neurotoxicity as compared to further treatment with cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer</measure>
    <time_frame>6 months after initiation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate to neoadjuvant chemotherapy with docetaxel/cisplatin in locally advanced squamous head and neck cancer</measure>
    <time_frame>3 months after initiation of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to chemoradiotherapy in locally advanced squamous head and neck cancer</measure>
    <time_frame>6 months after initiation of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer</measure>
    <time_frame>Every 3 weeks for 6 months (during therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival after neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant/Concomitant Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel/cisplatin</intervention_name>
    <description>Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles</description>
    <arm_group_label>Neoadjuvant/Concomitant Chemoradiation</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>70 Gy in 35 fractions to gross tumor and lymph node metastases</description>
    <arm_group_label>Neoadjuvant/Concomitant Chemoradiation</arm_group_label>
    <other_name>Radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 1.5 intravenous weekly during radiotherapy</description>
    <arm_group_label>Neoadjuvant/Concomitant Chemoradiation</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven locoregional Stage 4 squamous cell carcinoma of the oral cavity,
             larynx, oropharynx or hypopharynx

          -  Measurable or evaluable disease

          -  No distant metastases

          -  Tumor should be surgically unresectable for cure or resection is considered
             inadvisable

          -  Age &gt; 18 years

          -  ECOG performance status 0, 1 or 2

          -  Life expectancy &gt; 2 months

          -  Patients must have adequate organ and marrow function as defined below:

               -  Leukocytes &gt; 3,000/mm3

               -  Absolute neutrophil count &gt; 1,500/mm3

               -  Platelets &gt; 100,000/mm3

               -  Hemoglobin &gt; 10.0g/dL

               -  Total Bilirubin &lt;= institutional upper limit of normal

               -  Aspartate aminotransferase &lt; 2.5 X institutional upper limit of normal

               -  Alanine aminotransferase &lt; 2.5 X institutional upper limit of normal

               -  Alkaline phosphatase &lt; 2.5 X institutional upper limit of normal

               -  Creatinine &lt;= institutional upper limit of normal OR creatinine clearance &gt; 60
                  mL/min/1.73 m2 for patients with creatinine &gt; institutional upper limit of normal

          -  Signed informed consent

          -  Women of child-bearing potential and men must be willing and able practice adequate
             contraception prior to study entry and for the duration of study treatment

        Exclusion Criteria:

          -  Previous chemotherapy for this malignancy

          -  Previous radiotherapy to head and neck region

          -  Other malignancy within last 5 years except for non-melanoma skin cancer

          -  Uncontrolled intercurrent illness that would prevent delivery of protocol therapy

          -  Peripheral neuropathy &gt; Grade 2

          -  Hypercalcemia

          -  Patient is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Grunberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont/Feltcher Allen Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven M Grunberg, MD</last_name>
    <phone>802-847-8400</phone>
    <email>Steven.Grunberg@vtmednet.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madhuri V Vithala, MD</last_name>
    <phone>802-847-8400</phone>
    <email>Madhuri.Vithala@vtmednet.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mountainview Medical Center</name>
      <address>
        <city>Berlin</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Valentine, MD</last_name>
      <phone>802-225-5400</phone>
      <email>john.valentine@cvmc.org</email>
    </contact>
    <investigator>
      <last_name>John Valentine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Ospina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Fram, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Grunberg, MD</last_name>
      <phone>802-847-8400</phone>
      <email>Steven.Grunberg@vtmednet.org</email>
    </contact>
    <contact_backup>
      <last_name>Madhuri V Vithala, MD</last_name>
      <phone>802-847-8400</phone>
      <email>Madhuri.Vithala@vtmednet.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven M Grunberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madhuri V Vithala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Havaleh Gagne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Brundage, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vermont Center for Cancer Medicine</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Thomas, MD</last_name>
      <phone>802-655-3400</phone>
      <email>Christian.Thomas@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Paul Unger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Sanders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Nunnink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Steven Grunberg</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Head and neck neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

